$REPL: Q2 Earnings Preview — Capital Raise vs. Clinical Catalysts

Replimune reports Q2 Jun/2026 results; consensus expects EPS ($0.72). Focus shifts to cash runway after $150M offering and Gedeptin immuno-oncology updates.

Loading exclusive…

Key Points

Consensus EPS: ($0.72) vs ($0.95) prior year
$150M capital raise extends cash runway
Gedeptin tumor-priming strategy is key catalyst
Stock near 18-month highs on offering news

What To Watch

Cash runway extension details
Gedeptin clinical trial updates
R&D spend efficiency metrics
Forward guidance on oncology milestones

Market Analysis

How the tape may move from the last update’s mark — not from the open, and not the session % already printed.

The recent $150M offering has reset the cash runway, reducing near-term dilution risk. The stock’s rally to 18-month highs suggests the market is pricing in successful clinical execution for Gedeptin. Earnings will likely meet EPS consensus, but the reaction will depend on management’s ability to articulate a clear path for the new capital and provide positive updates on the immuno-oncology pipeline. Any ambiguity could lead to a pullback from recent highs.

Expected Move From Here -3.5% to +2.5% From last update, not from the open

Certainty 55%

Why

Biotech earnings are inherently volatile, especially post-capital raise. The range reflects the uncertainty of qualitative updates on Gedeptin. The lower bound accounts for potential disappointment in guidance or cash burn details, while the upper bound allows for positive sentiment on clinical milestones. The recent high price action adds downside risk if the narrative falters.

Related Sources

Why Did ABCL, REPL, ABNB Stocks Hit 52-Week Highs Today? — Stocktwits
REPL Stock Hits Near 18-Month High On Pricing Of $150M Offering – But, Retail Sees Share Price ‘Unwinding Over Time’ — Stocktwits
GeoVax Highlights Gedeptin(R) Tumor-Priming Strategy as Immuno-Oncology Enters New Phase — NewMediaWire
This Biotech’s Drug Could Treat Hot Flashes. The Stock Is Up 34% on Good News. — Wire
Replimune Prices $150 Million Offering — MT Newswires
Who backs Paxton, Talarico in Texas Senate race? See endorsement list — USA TODAY
Top Cryptocurrencies Mixed; Bitcoin Holds Above $63,000 Level — MT Newswires
Are Bonds Failing Retirees? This Advisor Thinks So — etf.com
Flex Finance Launches Connected Spend Management Platform for African Businesses — TMX Newsfile
JellyBlue Gummies Details Complete Supplement Facts Formulation for Male Vitality, Energy and Daily Wellness Support — GlobeNewswire